Discovery of New Autotaxin Inhibitors Using Structure-based Approaches

Meihui Nelson^*
*Correspondence: Meihui Nelson, Department of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan, Email:

Keywords

Autotaxin • Structure-based drug design • Computational chemistry

Introduction

AutoTaXin (ATX), an extracellular enzyme with lysophospholipase D activity, plays a pivotal role in lipid signaling pathways by catalyzing the conversion of LysophosPhatidylCholine (LPC) to LysoPhosphatidic Acid (LPA). Through its involvement in LPA signaling, ATX contributes to various physiological processes and pathological conditions, including cancer progression, inflammation, fibrosis and vascular disorders. Dysregulation of the ATX-LPA axis is implicated in the pathogenesis of these diseases, making ATX an attractive therapeutic target. Traditional drug discovery methods have been significantly augmented by structure-based approaches, which integrate computational modeling, structural biology insights and medicinal chemistry principles to design inhibitors that selectively target ATX. This review focuses on recent advancements in the field of ATX inhibitor discovery using structure-based approaches. It examines how computational techniques, such as molecular docking, molecular dynamics simulations and virtual screening, have been employed to identify potential ATX inhibitors and optimize their binding affinity and specificity [1].

Furthermore, it discusses the contributions of structural biology studies, including X-ray crystallography and cryo-electron microscopy, in elucidating the three-dimensional structure of ATX and its complexes with inhibitors. These structural insights have been pivotal in guiding rational drug design strategies aimed at developing potent and selective ATX inhibitors. By synthesizing knowledge from computational modeling, structural biology and medicinal chemistry, researchers have made significant strides in identifying novel chemical scaffolds and lead compounds targeting ATX. These advancements lay the groundwork for developing innovative therapeutic agents that could modulate the ATX-LPA signaling pathway for therapeutic benefit in various diseases. The following sections provide a comprehensive review of the current status, challenges, opportunities and future directions in the discovery of new autotaxin inhibitors using structure-based approaches [2].

Literature Review

Computational modeling plays a central role in structure-based drug design by predicting the binding modes and interactions between small molecule inhibitors and their target proteins, such as ATX. Molecular docking algorithms evaluate the binding affinity of potential inhibitors within the active site or allosteric pockets of ATX, providing insights into their molecular interactions and optimizing their chemical structures for enhanced potency. Molecular dynamics simulations further elucidate the dynamic behavior of ATX-inhibitor complexes, revealing conformational changes and stability over time. These computational techniques enable researchers to explore a vast chemical space, prioritize lead compounds and design derivatives with improved pharmacokinetic properties and selectivity profiles. Advances in structural biology techniques have yielded high-resolution structural data of ATX, offering unprecedented insights into its catalytic mechanism and substrate recognition [3].

X-ray crystallography and cryo-electron microscopy have elucidated the three-dimensional architecture of ATX and its complexes with inhibitors, revealing key residues involved in ligand binding and catalysis. Structural studies have identified distinct binding sites on ATX, including the catalytic site responsible for LPC hydrolysis and allosteric sites that modulate enzyme activity. These structural insights have guided the rational design of ATX inhibitors by targeting specific binding pockets and exploiting allosteric regulation to achieve desired pharmacological effects. Medicinal chemistry efforts focus on optimizing ATX inhibitors through Structure-Activity Relationship (SAR) studies, fragment-based drug design and scaffold hopping approaches. By systematically modifying chemical scaffolds and exploring diverse chemical space, researchers aim to improve inhibitor potency, selectivity against ATX over related enzymes and physicochemical properties favorable for oral bioavailability and drug-like characteristics [4].

Iterative cycles of computational predictions and experimental validation drive the optimization of lead compounds towards clinical candidates, balancing efficacy with safety and tolerability profiles in preclinical models. Preclinical studies have demonstrated the therapeutic potential of ATX inhibitors in various disease models characterized by dysregulated LPA signaling, including cancer metastasis, inflammatory diseases, pulmonary fibrosis and cardiovascular disorders. Promising lead compounds have shown efficacy in reducing tumor growth, inflammation and fibrotic tissue deposition by targeting ATX-mediated LPA production. Clinical translation of ATX inhibitors is underway, with early-phase trials evaluating safety, pharmacokinetics and preliminary efficacy in patient populations. Challenges include optimizing dosing regimens, patient selection criteria and biomarker identification to maximize therapeutic outcomes and minimize adverse effects in clinical settings [5].

Discussion

The discussion section synthesizes findings from computational modeling, structural biology insights, medicinal chemistry strategies and preclinical/clinical studies to evaluate the current landscape of ATX inhibitor discovery. It addresses challenges, such as the translation of in vitro efficacy to in vivo therapeutic efficacy, optimizing inhibitor selectivity against different ATX isoforms and overcoming potential resistance mechanisms in disease contexts. Furthermore, it explores opportunities for advancing structure-based approaches in ATX inhibitor development, including the integration of artificial intelligence and machine learning algorithms to predict novel chemical scaffolds and optimize lead compounds [6].

Conclusion

In conclusion, structure-based approaches have revolutionized the discovery of new autotaxin inhibitors, offering unprecedented opportunities to modulate the ATX-LPA signaling pathway for therapeutic benefit in cancer, inflammation, fibrosis and other diseases. Computational modeling, coupled with structural biology insights and medicinal chemistry innovations, has facilitated the rational design of ATX inhibitors with enhanced potency, selectivity and pharmacokinetic properties. Future research directions should focus on advancing lead compounds through preclinical and clinical development stages, validating their therapeutic efficacy in diverse disease models and optimizing treatment regimens tailored to individual patient needs.

By harnessing the synergistic capabilities of structure-based drug design, researchers can accelerate the translation of ATX inhibitors from bench to bedside, addressing unmet medical needs and improving patient outcomes in precision medicine. This comprehensive review underscores the transformative impact of structure-based approaches in ATX inhibitor discovery and highlights their potential to drive innovation in therapeutic interventions targeting ATX-associated diseases. This structured review provides a detailed exploration of the discovery of new autotaxin inhibitors using structure-based approaches, encompassing computational modeling, structural biology insights, medicinal chemistry strategies, preclinical/clinical developments and future research directions.

Acknowledgement

None.

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

1. Magkrioti, Christiana, Apostolos Galaris, Paraskevi Kanellopoulou and Elli-Anna Stylianaki, et al. "Autotaxin and chronic inflammatory diseases." J Autoimmun 104 (2019): 102327.

Google Scholar, Crossref, Indexed at

2. Umezu-Goto, Makiko, Yasuhiro Kishi, Akitsu Taira and Kotaro Hama, et al. "Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production." J Cell Biol 158 (2002): 227-233.

Google Scholar, Crossref, Indexed at

3. Tokumura, Akira, Eiji Majima, Yuko Kariya and Kyoko Tominaga, et al. "Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase." J Biol Chem 277 (2002): 39436-39442.

Google Scholar, Crossref, Indexed at

4. Yung, Yun C., Nicole C. Stoddard and Jerold Chun. "LPA receptor signaling: Pharmacology, physiology and pathophysiology." J Lipid Res 55 (2014): 1192-1214.

Google Scholar, Crossref, Indexed at

5. Tang, Xiaoyun, Melinda Wuest, Matthew GK Benesch and Jennifer Dufour, et al. "Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer." Mol Cancer Ther 19 (2020): 63-74.

Google Scholar, Crossref, Indexed at

6. Banerjee, Souvik, Derek D. Norman, Sue Chin Lee and Abby L. Parrill, et al. "Highly potent non-carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells." J Med Chem 60 (2017): 1309-1324.

Google Scholar, Crossref, Indexed at